Immutep 2023 Corporate Presentation - LAG-3 Immunotherapy

Immutep Limited is a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for oncology and autoimmune diseases. The presentation highlights eftilagimod alpha's compelling efficacy data, including doubling overall response rates of anti-PD-1 monotherapy, supported by oral presentations at ASCO and SITC conferences in 2022. The company leverages collaborations with industry leaders and maintains a global presence in advancing cancer and autoimmune disease treatments.